Abstract
Angiogenesis is one of the hallmarks of cancer progression and as such has been considered a target of therapeutic interest. However, single targeted agents have not fully lived up to the initial promise of anti-angiogenic therapy. Therefore, it has been suggested that combining therapies and agents will be the way forward in the oncology field. In recent years, microRNAs (miRNAs) have received considerable attention as drivers of tumor development and progression, either acting as tumor suppressors or as oncogenes (so-called oncomiRs), as well as in the process of tumor angiogenesis (angiomiRs). Not only from a functional, but also from a therapeutic view, miRNAs are attractive tools. Thus far, several mimics and antagonists of miRNAs have entered clinical development. Here, we review the provenance and promise of miRNAs as targets as well as therapeutics to contribute to anti-angiogenesis-based (combination) treatment of cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 269-285 |
| Number of pages | 17 |
| Journal | Angiogenesis |
| Volume | 20 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - May 2017 |
Cite this
}
miRNAs : micro-managers of anticancer combination therapies. / van Beijnum, Judy R; Giovannetti, Elisa; Poel, Dennis; Nowak-Sliwinska, Patrycja; Griffioen, Arjan W.
In: Angiogenesis, Vol. 20, No. 2, 05.2017, p. 269-285.Research output: Contribution to journal › Review article › Academic › peer-review
TY - JOUR
T1 - miRNAs
T2 - micro-managers of anticancer combination therapies
AU - van Beijnum, Judy R
AU - Giovannetti, Elisa
AU - Poel, Dennis
AU - Nowak-Sliwinska, Patrycja
AU - Griffioen, Arjan W
PY - 2017/5
Y1 - 2017/5
N2 - Angiogenesis is one of the hallmarks of cancer progression and as such has been considered a target of therapeutic interest. However, single targeted agents have not fully lived up to the initial promise of anti-angiogenic therapy. Therefore, it has been suggested that combining therapies and agents will be the way forward in the oncology field. In recent years, microRNAs (miRNAs) have received considerable attention as drivers of tumor development and progression, either acting as tumor suppressors or as oncogenes (so-called oncomiRs), as well as in the process of tumor angiogenesis (angiomiRs). Not only from a functional, but also from a therapeutic view, miRNAs are attractive tools. Thus far, several mimics and antagonists of miRNAs have entered clinical development. Here, we review the provenance and promise of miRNAs as targets as well as therapeutics to contribute to anti-angiogenesis-based (combination) treatment of cancer.
AB - Angiogenesis is one of the hallmarks of cancer progression and as such has been considered a target of therapeutic interest. However, single targeted agents have not fully lived up to the initial promise of anti-angiogenic therapy. Therefore, it has been suggested that combining therapies and agents will be the way forward in the oncology field. In recent years, microRNAs (miRNAs) have received considerable attention as drivers of tumor development and progression, either acting as tumor suppressors or as oncogenes (so-called oncomiRs), as well as in the process of tumor angiogenesis (angiomiRs). Not only from a functional, but also from a therapeutic view, miRNAs are attractive tools. Thus far, several mimics and antagonists of miRNAs have entered clinical development. Here, we review the provenance and promise of miRNAs as targets as well as therapeutics to contribute to anti-angiogenesis-based (combination) treatment of cancer.
KW - Animals
KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
KW - Humans
KW - MicroRNAs/metabolism
KW - Neoplasms/blood supply
KW - Neovascularization, Pathologic/drug therapy
KW - RNA, Neoplasm/metabolism
U2 - 10.1007/s10456-017-9545-x
DO - 10.1007/s10456-017-9545-x
M3 - Review article
VL - 20
SP - 269
EP - 285
JO - Angiogenesis
JF - Angiogenesis
SN - 0969-6970
IS - 2
ER -